IFNB1 and glioblastoma: The detrimental effect of TMZ on AAV gene therapy may not be a significant limitation in clinical practice as chemotherapy usually starts 4 weeks after surgery in patients with glioblastoma (Mao et al., 2015; Stupp et al., 2005), and thus, local injection of AAV‐IFN‐β vectors in the brain tissue immediately after surgical resection of tumors would be a viable option.